Browse the evidence

Whey protein supplementation (Concentrate and Hydrolysate) increases skeletal muscle satellite cell counts compared to baseline, whereas soy and leucine do not, suggesting a potential mechanism for long-term adaptation despite no immediate hypertrophy benefit.

While whey, soy, and leucine all support similar muscle size gains in beginners, whey might offer a unique benefit by increasing satellite cells (muscle repair cells). This might not show up in 12 weeks, but could be beneficial for long-term training. If you prefer whey, this is a potential bonus, but it's not a requirement for growth.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is bidirectionally associated with the development and progression of cardiovascular, renal, and metabolic disorders, acting as both a driver and consequence of systemic cardiometabolic dysfunction.

If you have fatty liver (MASLD), it is not just a liver issue; it significantly increases your risk for heart disease, kidney disease, and diabetes. You need to manage your metabolic health (weight, blood sugar, blood pressure) comprehensively to protect your heart and kidneys, not just your liver.

SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone demonstrate benefits across multiple cardiometabolic conditions, improving clinical outcomes in patients with MASLD, CKD, and CVD.

Current medications like SGLT2 inhibitors, GLP-1 agonists, and finerenone are effective for treating multiple aspects of cardiometabolic disease simultaneously. Discuss these options with your doctor if you have liver, kidney, or heart issues.

Supplementing plant-based proteins (specifically soy or pea) with extra leucine or essential amino acids can equalize the muscle protein synthesis response to whey protein, but long-term supplementation with leucine alone does not increase muscle mass or strength in older adults.

Do not rely on leucine supplements alone to build muscle. While adding leucine to a small plant-protein meal can make it work as well as a larger animal-protein meal for immediate muscle signaling, taking leucine pills on top of your normal diet has not been shown to increase muscle mass or strength in older adults. Focus on eating enough total protein from whole foods or complete plant proteins instead.

Menopause triggers a shift in body composition toward increased visceral and perivascular fat and reduced fat-free mass, independent of modest total weight gain, driven by estrogen deficiency and elevated FSH.

Do not rely on the scale alone during menopause. Your risk is increasing even if your weight stays stable because you are losing muscle and gaining dangerous visceral fat. Measure your waist circumference and prioritize resistance training to preserve muscle mass.

Estrogen replacement therapy (ERT) and progestin therapy reduce BMI, waist circumference, fasting insulin, and the incidence of new diabetes compared to placebo.

If you are experiencing menopausal symptoms and metabolic risks, discuss Hormone Replacement Therapy (HRT) with your doctor. It may help lower your risk of developing type 2 diabetes and improve body composition, though you must weigh this against potential side effects.

Energy-restricted diets result in modest long-term weight loss (approx. 3% maintained at 5 years) and high relapse rates (>80%) due to compensatory metabolic adaptations including increased hunger hormones (ghrelin), decreased satiety hormones (leptin, GLP-1, PYY), and reduced energy expenditure.

Standard calorie restriction often fails long-term because your body fights back by increasing hunger hormones and lowering metabolism. To succeed, you must manage these biological responses, likely by prioritizing high protein intake to help suppress hunger hormones like ghrelin and preserve metabolic rate, rather than just cutting calories blindly.

Tirzepatide (5-15 mg once weekly) significantly reduces the risk of composite kidney endpoints (eGFR decline ≥40%, renal death, kidney failure, or new-onset macroalbuminuria) in patients with type 2 diabetes and high cardiovascular risk compared to insulin glargine.

If you have type 2 diabetes and are at high risk for heart or kidney problems, tirzepatide (a once-weekly injection) has been shown to significantly reduce the risk of serious kidney issues compared to insulin glargine. This benefit includes slowing the decline in kidney function and preventing the onset of severe protein in the urine. While there may be an initial, reversible drop in kidney function numbers, this is a sign of reduced stress on the kidneys. Always consult your doctor to see if this treatment is appropriate for your specific health profile.

BCAA supplementation activates anabolic signaling pathways (mTORC1) and improves hormonal profiles (testosterone/cortisol ratio) in the short term, but this does not translate to long-term muscle or strength gains if total protein intake is adequate.

BCAAs do trigger muscle-building signals in your body, but this doesn't mean you will gain muscle or strength. If you are eating enough protein from food, BCAAs add no value. Do not use them to try to 'boost' your muscle growth.

Time-restricted eating (TRE) improves metabolic health markers (insulin sensitivity, glucose control) independent of weight loss when the eating window is aligned with circadian rhythms (early/mid-TRE), whereas late or self-selected windows show little to no benefit.

If you want to try Time-Restricted Eating, start by shifting your eating window to the earlier part of the day (e.g., 8am to 4pm or 10am to 6pm) rather than skipping breakfast or eating late at night. Keep your food choices normal (ad libitum) but ensure you finish eating before 8pm. This alignment with your body's natural circadian rhythms is what drives metabolic improvements, independent of weight loss.

Liraglutide improves insulin sensitivity (measured by HOMA-IR, HOMA2, and Matsuda index) rapidly, within 2 weeks, independent of weight loss.

If you have obesity and prediabetes, liraglutide improves how your body handles insulin within two weeks, even before you lose significant weight. This is a direct drug effect, not just a result of dieting.

Combination therapy using GLP-1 receptor agonists with other hormones (GIP, GCG, or PYY) mimics the beneficial hormonal effects of gastric bypass surgery in non-surgical patients.

New combination drugs that activate multiple gut hormone receptors (like GLP-1, GIP, and Glucagon) are showing strong results in clinical trials for weight loss and blood sugar control, offering a non-surgical alternative to gastric bypass.

Fasting induces a metabolic switch from glycogenolysis to gluconeogenesis, lipolysis, and ketogenesis, which is considered a main driver of the metabolic health benefits provided by IF.

During fasting, your body switches from burning sugar to burning fat and producing ketones. This metabolic shift is likely why fasting can be healthy, even if it doesn't always lead to more weight loss than just eating less.

Daily ingestion of yogurt containing heat-treated Lactobacillus plantarum OLL2712 (≥5×10^9 cells) for 12 weeks significantly reduces HbA1c levels in prediabetic adults compared to placebo, primarily by preventing the aggravation of chronic inflammation and insulin resistance.

If you are prediabetic, eating 112 grams of yogurt containing heat-treated Lactobacillus plantarum OLL2712 every day for 3 months can help lower your average blood sugar (HbA1c) more than eating regular yogurt. It works by calming chronic inflammation that drives insulin resistance. You do not need to change your diet or exercise routine for this to work, but you should maintain your normal habits.

In prediabetic adults with higher baseline fasting blood glucose (≥107 mg/dL) or insulin resistance (HOMA-IR > 1.6), daily ingestion of heat-treated Lactobacillus plantarum OLL2712 significantly reduces fasting blood glucose and glycoalbumin levels, whereas no significant change occurs in the general population with lower baseline glucose.

If you are prediabetic and have higher fasting blood sugar or insulin resistance, adding this specific yogurt to your daily routine for 3 months may help lower your fasting blood sugar. If your baseline blood sugar is already in the normal range, you might not see a change in fasting levels, though your average blood sugar (HbA1c) may still improve slightly.

Obesity and Type 2 Diabetes are associated with altered secretion patterns of enteroendocrine hormones, specifically decreased GLP-1 and PYY, and increased ghrelin.

In obesity and diabetes, your gut's natural hormone signals are often disrupted, with less 'satiety' hormone (GLP-1) and more 'hunger' hormone (ghrelin). This contributes to the difficulty in managing weight.

Fructose consumption, particularly in large amounts or from added sugars, stimulates hepatic de novo lipogenesis and VLDL-triglyceride secretion, increasing intrahepatic fat and cardiovascular risk, whereas glucose and starch have different, often less adverse, metabolic profiles.

Limit added sugars, particularly those high in fructose (like HFCS and sucrose), as they can promote liver fat accumulation and high triglycerides. While whole fruits are healthy due to fiber, be mindful of concentrated fructose sources. Physical activity can mitigate some of these effects by increasing fructose oxidation.

GLP-1 RAs reduce blood pressure and albuminuria in patients with CKD and overweight/obesity, contributing to kidney and cardiovascular protection.

GLP-1 RAs can help lower your blood pressure and reduce protein in your urine (albuminuria), which are important markers for kidney and heart health. This benefit is partly due to weight loss but also direct effects of the medication.

Gut hormones (GLP-1, GIP, CCK, PYY, OXM) regulate food intake and energy homeostasis by acting on the hypothalamus and brainstem via direct circulation or vagus nerve signaling, while ghrelin stimulates appetite.

Understanding that gut hormones like GLP-1 and GIP signal satiety to the brain helps explain why medications mimicking these hormones (like semaglutide and tirzepatide) are effective for weight loss. Conversely, ghrelin signals hunger. This biological basis supports the use of drugs that target these pathways.

NNC9204-1177, a glucagon/GLP-1 receptor co-agonist, produces dose-dependent, clinically relevant weight loss (up to 12.6%) in adults with overweight or obesity, but its clinical development was halted due to unexpected safety signals including increased heart rate, impaired glucose tolerance, and elevated inflammatory markers.

NNC9204-1177 is not available for clinical use because it caused unacceptable side effects like rapid heart rate and inflammation, despite causing significant weight loss. Do not seek this specific compound. However, the mechanism (glucagon/GLP-1 co-agonism) suggests that combining these pathways can be more effective for weight loss than GLP-1 alone, provided safety is managed. Current approved GLP-1 agonists (like semaglutide) do not have this glucagon component and thus avoid this specific safety profile.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce liver fat content and improve histological markers of NASH (resolution without fibrosis worsening) in patients with NAFLD, with efficacy demonstrated across liraglutide, semaglutide, and tirzepatide.

If you have fatty liver disease (NAFLD) or NASH, GLP-1 medications like liraglutide, semaglutide, or tirzepatide are proven to reduce liver fat and improve liver health, often more effectively than placebo. These drugs work through hormonal mechanisms that reduce liver fat independently of weight loss in some cases. While gastrointestinal side effects like nausea are common, they are often manageable. Consult a doctor to see if you are a candidate, especially if you also have Type 2 Diabetes or obesity.

The combination of bupropion and naltrexone reduces body weight by stimulating POMC neurons to decrease energy intake and increase expenditure, with naltrexone blocking negative feedback to enhance this effect.

Bupropion/naltrexone is a combination pill that helps reduce appetite and increase energy expenditure by acting on brain pathways. It is effective for weight loss in people with obesity and comorbidities like hypertension or diabetes. However, it is not suitable for everyone, particularly those with a history of seizures or eating disorders. Consult your doctor to determine if it is safe for you.

The co-ingestion of protein and calcium produces a synergistic, potent stimulation of endogenous GLP-1 secretion that exceeds the effects of either nutrient alone.

To maximize your body's natural appetite-suppressing hormone (GLP-1), combine protein and calcium in your meals. Research shows this combination triggers a much stronger hormonal response than eating protein or calcium alone. This is a natural, side-effect-free way to support satiety and metabolic health.

Female sex is significantly associated with a hyper-response (>15% total body weight loss) to subcutaneous GLP-1 analogue therapy compared to non-response, whereas male sex is not.

If you are a woman taking a GLP-1 medication like semaglutide or liraglutide for obesity, you are statistically more likely to achieve significant weight loss (hyper-response) than a man taking the same medication. This is likely due to physiological differences in how your body processes the drug and regulates appetite hormones. Men may need higher doses to achieve similar results. If you are not losing weight, discuss dose adjustment or alternative treatments with your doctor rather than stopping abruptly.